Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Trimethylammonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 known ✓ | O15379 | 4/20 | 0.42 |
| ▸ | HDAC1 known ✓ | Q13547 | 4/20 | 0.42 |
| ▸ | HDAC2 known ✓ | Q92769 | 4/20 | 0.42 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 4/20 | 0.42 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.33 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 3/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | TET2 | Q6N021 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TET3 | O43151 | 1/20 | 0.33 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.32 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimethylammonium SCHEMBL964726 | 1.00 | HDAC3 (0.42) | HDAC3HDAC1HDAC2HDAC8FFAR3 | |
| Trimethylammonium SCHEMBL29766120 | 0.98 | HDAC3 (0.43) | HDAC3HDAC1HDAC2HDAC8FFAR3 | |
| Trimethylammonium SCHEMBL180002 | 0.98 | HDAC3 (0.43) | HDAC3HDAC1HDAC2HDAC8FFAR3 | |
| Trimethylammonium SCHEMBL154411 | 0.95 | HDAC3 (0.42) | HDAC3HDAC1HDAC2HDAC8FFAR3 | |
| Trimethylammonium SCHEMBL1424158 | 0.95 | HDAC3 (0.42) | HDAC3HDAC1HDAC2HDAC8FFAR3 | |
| Trimethylammonium SCHEMBL5988078 | 0.94 | FFAR3 (0.37) | HDAC3HDAC1HDAC2HDAC8FFAR3 | |
| Methacrylic Acid SCHEMBL5987963 | 0.94 | FFAR3 (0.37) | HDAC3HDAC1HDAC2HDAC8FFAR3 | |
| Trimethylammonium SCHEMBL524378 | 0.94 | FFAR3 (0.37) | HDAC3HDAC1HDAC2HDAC8FFAR3 | |
| Hydrochloric Acid SCHEMBL2564981 | 0.93 | — | — | |
| Methacrylic Acid SCHEMBL17003924 | 0.91 | FFAR3 (0.39) | HDAC3HDAC1HDAC2HDAC8FFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1777 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115171-A1 | PHARMACEUTICAL COMPOSITION | KOWA COMPANY, LTD. (JP) | 2026-04-30 | — | — | US | claimed |
| US-20260115141-A1 | PHARMACEUTICAL PREPARATION | KOWA COMPANY, LTD. (JP) | 2026-04-30 | — | — | US | claimed |
| US-12522763-B1 | Relative permeability modifier package for produced fluids from a subterranean formation | HALLIBURTON ENERGY SERVICES, INC. (US) | 2026-01-13 | — | — | US | claimed |
| US-20250332120-A1 | COMPOSITION FOR EXTERNAL PREPARATION | KAO CORPORATION (JP) | 2025-10-30 | — | — | US | claimed |
| US-12350120-B1 | Gum-protecting and teeth-whitening strip and preparation method thereof | Jiangxi Dentalbright Technology Co., Ltd. (CN) | 2025-07-08 | — | — | US | claimed |
| WO-2025124483-A1 | ORAL DRUG DOSAGE FORM FOR TARGETED DRUG DELIVERY BASED ON TRACKING MARKER AND METHODS OF DESIGN AND USE THEREOF | Triastek, Inc. (CN) | 2025-06-19 | — | — | WO | claimed |
| CN-120154576-A | Child dosage forms, methods of manufacture and use | 欧普科爱尔兰环球控股有限公司 | 2025-06-17 | — | — | CN | claimed |
| US-12210284-B2 | Photosensitive composition | XSYS GERMANY GMBH (DE) | 2025-01-28 | — | — | US | claimed |
| US-20240115528-A1 | COMPOSITION FOR EXTERNAL APPLICATION | KAO CORPORATION (JP) | 2024-04-11 | — | — | US | claimed |
| CN-117715632-A | Compositions comprising an enzyme-cleavable prodrug and nafamostat and methods of use thereof | 恩赛斯生物科学股份有限公司 | 2024-03-15 | — | — | CN | claimed |
| US-5622721-A | PROTECTIVE COATINGS FOR SUSTAIN RELEASE, INSOLUBLE IN ACIDITY | THE PROCTER & GAMBLE COMPANY (US) | 1997-04-22 | — | — | US | claimed |
| EP-0386967-B1 | A drug-release controlling coating material for long acting formulations | YAMANOUCHI PHARMA CO LTD (JP) | 1995-07-12 | — | — | EP | claimed |
| EP-0415671-B1 | Gastric retention device | YAMANOUCHI PHARMA CO LTD (JP) | 1995-03-29 | — | — | EP | claimed |
| US-5395628-A | Controlled release succinic acid microcapsules coated with aqueous acrylics | TANABE SEIYAKU CO., LTD. (JP) | 1995-03-07 | — | — | US | claimed |
| US-5316772-A | Bilayered oral pharmaceutical composition with pH dependent release | SOLVAY & CIE, S.A. (SOCIETE ANONYME) (BE) | 1994-05-31 | — | — | US | claimed |
| EP-0436370-B1 | CONTROLLED RELEASE PHARMACEUTICAL PREPARATION AND METHOD FOR PRODUCING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 1993-08-04 | — | — | EP | claimed |
| WO-1992011001-A1 | ORAL PHARMACEUTICAL COMPOSITION | SOLVAY (SOCIETE ANONYME) (BE) | 1992-07-09 | — | — | WO | claimed |
| EP-0436370-A1 | Controlled release pharmaceutical preparation and method for producing the same | TANABE SEIYAKU CO., LTD. (JP) | 1991-07-10 | — | — | EP | claimed |
| EP-0148811-B1 | PHARMACEUTICAL COMPOSITION | LEJUS MEDICAL AKTIEBOLAG (SE) | 1989-09-06 | — | — | EP | claimed |
| EP-0287536-A1 | Pharmaceutical quinidine composition | LEJUS MEDICAL AKTIEBOLAG (SE) | 1988-10-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115141-A1 | PHARMACEUTICAL PREPARATION | PPARA, FABP1, MTTP | HDAC3 670/4885HDAC1 1170/4885HDAC2 1670/4885 |
| US-20260115171-A1 | PHARMACEUTICAL COMPOSITION | PPARA, FABP1, LIPC | HDAC3 391/4885HDAC1 626/4885HDAC2 1153/4885 |
| US-12350120-B1 | Gum-protecting and teeth-whitening strip and preparation method thereof | TAS2R30, TAS2R60, TAS2R14 | HDAC3 1792/4885HDAC1 886/4885HDAC2 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.